272 related articles for article (PubMed ID: 34593524)
1. MTH1 Inhibitor TH1579 Induces Oxidative DNA Damage and Mitotic Arrest in Acute Myeloid Leukemia.
Sanjiv K; Calderón-Montaño JM; Pham TM; Erkers T; Tsuber V; Almlöf I; Höglund A; Heshmati Y; Seashore-Ludlow B; Nagesh Danda A; Gad H; Wiita E; Göktürk C; Rasti A; Friedrich S; Centio A; Estruch M; Våtsveen TK; Struyf N; Visnes T; Scobie M; Koolmeister T; Henriksson M; Wallner O; Sandvall T; Lehmann S; Theilgaard-Mönch K; Garnett MJ; Östling P; Walfridsson J; Helleday T; Warpman Berglund U
Cancer Res; 2021 Nov; 81(22):5733-5744. PubMed ID: 34593524
[TBL] [Abstract][Full Text] [Related]
2. AXL and CAV-1 play a role for MTH1 inhibitor TH1579 sensitivity in cutaneous malignant melanoma.
Das I; Gad H; Bräutigam L; Pudelko L; Tuominen R; Höiom V; Almlöf I; Rajagopal V; Hansson J; Helleday T; Egyházi Brage S; Warpman Berglund U
Cell Death Differ; 2020 Jul; 27(7):2081-2098. PubMed ID: 31919461
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Oxidized Nucleotide Sanitation By TH1579 and Conventional Chemotherapy Cooperatively Enhance Oxidative DNA Damage and Survival in AML.
Centio A; Estruch M; Reckzeh K; Sanjiv K; Vittori C; Engelhard S; Warpman Berglund U; Helleday T; Theilgaard-Mönch K
Mol Cancer Ther; 2022 May; 21(5):703-714. PubMed ID: 35247918
[TBL] [Abstract][Full Text] [Related]
4. TH1579, MTH1 inhibitor, delays tumour growth and inhibits metastases development in osteosarcoma model.
Moukengue B; Brown HK; Charrier C; Battaglia S; Baud'huin M; Quillard T; Pham TM; Pateras IS; Gorgoulis VG; Helleday T; Heymann D; Berglund UW; Ory B; Lamoureux F
EBioMedicine; 2020 Mar; 53():102704. PubMed ID: 32151797
[TBL] [Abstract][Full Text] [Related]
5. SYK inhibition targets acute myeloid leukemia stem cells by blocking their oxidative metabolism.
Polak A; Bialopiotrowicz E; Krzymieniewska B; Wozniak J; Stojak M; Cybulska M; Kaniuga E; Mikula M; Jablonska E; Gorniak P; Noyszewska-Kania M; Szydlowski M; Piechna K; Piwocka K; Bugajski L; Lech-Maranda E; Barankiewicz J; Kolkowska-Lesniak A; Patkowska E; Glodkowska-Mrowka E; Baran N; Juszczynski P
Cell Death Dis; 2020 Nov; 11(11):956. PubMed ID: 33159047
[TBL] [Abstract][Full Text] [Related]
6. FLT3-ITD cooperates with Rac1 to modulate the sensitivity of leukemic cells to chemotherapeutic agents via regulation of DNA repair pathways.
Wu M; Li L; Hamaker M; Small D; Duffield AS
Haematologica; 2019 Dec; 104(12):2418-2428. PubMed ID: 30975911
[TBL] [Abstract][Full Text] [Related]
7. Karonudib has potent anti-tumor effects in preclinical models of B-cell lymphoma.
Oksvold MP; Berglund UW; Gad H; Bai B; Stokke T; Rein ID; Pham T; Sanjiv K; Øy GF; Norum JH; Smeland EB; Myklebust JH; Helleday T; Våtsveen TK
Sci Rep; 2021 Mar; 11(1):6317. PubMed ID: 33737576
[TBL] [Abstract][Full Text] [Related]
8. Adaptation to Chronic-Cycling Hypoxia Renders Cancer Cells Resistant to MTH1-Inhibitor Treatment Which Can Be Counteracted by Glutathione Depletion.
Hansel C; Hlouschek J; Xiang K; Melnikova M; Thomale J; Helleday T; Jendrossek V; Matschke J
Cells; 2021 Nov; 10(11):. PubMed ID: 34831264
[TBL] [Abstract][Full Text] [Related]
9. Iron Oxide Nanoparticles Combined with Cytosine Arabinoside Show Anti-Leukemia Stem Cell Effects on Acute Myeloid Leukemia by Regulating Reactive Oxygen Species.
Dou J; Li L; Guo M; Mei F; Zheng D; Xu H; Xue R; Bao X; Zhao F; Zhang Y
Int J Nanomedicine; 2021; 16():1231-1244. PubMed ID: 33633448
[TBL] [Abstract][Full Text] [Related]
10. Blast cells surviving acute myeloid leukemia induction therapy are in cycle with a signature of FOXM1 activity.
Williams MS; Basma NJ; Amaral FMR; Wiseman DH; Somervaille TCP
BMC Cancer; 2021 Oct; 21(1):1153. PubMed ID: 34711181
[TBL] [Abstract][Full Text] [Related]
11. Disulfiram/copper selectively eradicates AML leukemia stem cells in vitro and in vivo by simultaneous induction of ROS-JNK and inhibition of NF-κB and Nrf2.
Xu B; Wang S; Li R; Chen K; He L; Deng M; Kannappan V; Zha J; Dong H; Wang W
Cell Death Dis; 2017 May; 8(5):e2797. PubMed ID: 28518151
[TBL] [Abstract][Full Text] [Related]
12. Validation and development of MTH1 inhibitors for treatment of cancer.
Warpman Berglund U; Sanjiv K; Gad H; Kalderén C; Koolmeister T; Pham T; Gokturk C; Jafari R; Maddalo G; Seashore-Ludlow B; Chernobrovkin A; Manoilov A; Pateras IS; Rasti A; Jemth AS; Almlöf I; Loseva O; Visnes T; Einarsdottir BO; Gaugaz FZ; Saleh A; Platzack B; Wallner OA; Vallin KS; Henriksson M; Wakchaure P; Borhade S; Herr P; Kallberg Y; Baranczewski P; Homan EJ; Wiita E; Nagpal V; Meijer T; Schipper N; Rudd SG; Bräutigam L; Lindqvist A; Filppula A; Lee TC; Artursson P; Nilsson JA; Gorgoulis VG; Lehtiö J; Zubarev RA; Scobie M; Helleday T
Ann Oncol; 2016 Dec; 27(12):2275-2283. PubMed ID: 27827301
[TBL] [Abstract][Full Text] [Related]
13. Low-dose triptolide enhances antitumor effect of JQ1 on acute myeloid leukemia through inhibiting RNA polymerase II in vitro and in vivo.
Shi Y; Zhao H; Ye J; Li Z; Deng M; Zha J; Zhou Y; Zeng H; Lin Y; Pu X; Guo C; Song H; Qiu Y; Xu B
Mol Carcinog; 2020 Sep; 59(9):1076-1087. PubMed ID: 32691884
[TBL] [Abstract][Full Text] [Related]
14. Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML.
Herrmann H; Blatt K; Shi J; Gleixner KV; Cerny-Reiterer S; Müllauer L; Vakoc CR; Sperr WR; Horny HP; Bradner JE; Zuber J; Valent P
Oncotarget; 2012 Dec; 3(12):1588-99. PubMed ID: 23249862
[TBL] [Abstract][Full Text] [Related]
15. Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia.
Alachkar H; Santhanam R; Harb JG; Lucas DM; Oaks JJ; Hickey CJ; Pan L; Kinghorn AD; Caligiuri MA; Perrotti D; Byrd JC; Garzon R; Grever MR; Marcucci G
J Hematol Oncol; 2013 Mar; 6():21. PubMed ID: 23497456
[TBL] [Abstract][Full Text] [Related]
16. Examination of CD302 as a potential therapeutic target for acute myeloid leukemia.
Lo TH; Abadir E; Gasiorowski RE; Kabani K; Ramesh M; Orellana D; Fromm PD; Kupresanin F; Newman E; Cunningham I; Hart DNJ; Silveira PA; Clark GJ
PLoS One; 2019; 14(5):e0216368. PubMed ID: 31075107
[TBL] [Abstract][Full Text] [Related]
17. Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells.
Li Y; Wang Y; Zhou Y; Li J; Chen K; Zhang L; Deng M; Deng S; Li P; Xu B
Clin Epigenetics; 2017; 9():83. PubMed ID: 28814980
[TBL] [Abstract][Full Text] [Related]
18. Synthetic lethality of combined AT-101 with idarubicin in acute myeloid leukemia via blockade of DNA repair and activation of intrinsic apoptotic pathway.
Yang Q; Chen K; Zhang L; Feng L; Fu G; Jiang S; Bi S; Lin C; Zhou Y; Zhao H; Chen XL; Fu G; Xu B
Cancer Lett; 2019 Oct; 461():31-43. PubMed ID: 31301319
[TBL] [Abstract][Full Text] [Related]
19. Targeting sphingosine kinase 1 induces MCL1-dependent cell death in acute myeloid leukemia.
Powell JA; Lewis AC; Zhu W; Toubia J; Pitman MR; Wallington-Beddoe CT; Moretti PA; Iarossi D; Samaraweera SE; Cummings N; Ramshaw HS; Thomas D; Wei AH; Lopez AF; D'Andrea RJ; Lewis ID; Pitson SM
Blood; 2017 Feb; 129(6):771-782. PubMed ID: 27956387
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-9 promotes proliferation of leukemia cells in adult CD34-positive acute myeloid leukemia with normal karyotype by downregulation of Hes1.
Tian C; You MJ; Yu Y; Zhu L; Zheng G; Zhang Y
Tumour Biol; 2016 Jun; 37(6):7461-71. PubMed ID: 26678889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
